Time filter

Source Type

Plzeň, Czech Republic

Presl J.,Faculty Hospital in Pilsen | Novotny Z.,Faculty Hospital in Pilsen | Topolcan O.,Laboratory of Immunoanalysis | Vlasak P.,Faculty Hospital in Pilsen | And 6 more authors.
Anticancer Research

Aim: The aim of the present study was to compare the use of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) biomarkers in patients with endometrial cancer for preoperative management and to particularly focus on relationship between CA125 and HE4 and disease stage in predicting myometrial invasion or intrauterine tumor spread. Patients and Methods: Thirty-four patients diagnosed with endometrial cancer and 32 healthy controls were enrolled into the pilot study in the period between May 2012 and March 2013. Blood from all the females was collected and examined for CA125 and HE4. Based on standardized ultrasound examination, including gynecological examination, the clinical disease stage was determined. Results: We found a significant difference (p<0.0001) for means of serum levels of HE4: females with endometrial cancer, 75.5 pmol/l, versus healthy females, 40.0 pmol/l. A non-significant statistical difference was found for mean serum CA125 levels (p=0.4442): females with endometrial cancer 19.0 IU/l, versus healthy females, 15 IU/l. A significant correlation with histopathological disease stage was found for both biomarkers (Spearman correlation). Sensitivity and specificity, and the related cut-off for HE4 suggest that HE4 would be a more appropriate biomarker for differential diagnosis between benign and malignant states. Conclusion: Based on our pilot study, we found that parallel examination of HE4 and CA125 may support endometrial ultrasound finding verification prior to biopsy. This study is ongoing and we expect that results on a larger population may enable HE4 measurement to be implemented in routine practice. © 2014, International Institute of Anticancer Research. All rights reserved. Source

Kucera R.,Laboratory of Immunoanalysis | Ulcova-Gallova Z.,Medical Faculty | Windrichova J.,Laboratory of Immunoanalysis | Losan P.,Genetics Pilsen | Topolcan O.,Laboratory of Immunoanalysis
Systems Biology in Reproductive Medicine

ABSTRACT: Anti-Müllerian hormone (AMH) is a factor most associated with female fertility and especially with the ovarian reserve. AMH is also used as a parameter of fertility in men as it arises from the epithelium of the seminiferous tubules that contain Sertoli cells which produce the AMH. To investigate the relationship between AMH production and sperm related parameters we compared the AMH levels in serum and seminal plasma between a group of healthy males (n=65) and male patients (n=68) of infertile couples with semen pathology. We assessed the following fertility parameters: sperm count (SC), presence of intra-acrosomal enzymes (IAE), and antispermatozoal antibodies (ASA). Infertile men were divided into four subgroups according to: SC less than 15 million, SC less than 15 million and lack of IAE, SC less than 15 million and presence of ASA, presence of all three pathological parameters. The mean AMH serum level in the healthy group was 6.95 ng/ml and no significant difference was observed in serum AMH levels. The mean AMH seminal plasma level in the healthy group was 14.21 ng/ml. We observed a statistically significant decrease in the group with a SC with less than 15 million (3.29 ng/ml, p=0.0001) sperm, in the group with SC less than 15 million sperm and lack of IAE (3.95 ng/ml, p=0.0046), and in the group with all three pathological parameters (2.65 ng/ml, p=<0.0001). No significant difference was observed in the group with SC less than 15 million sperm and ASA positivity (11.41 ng/ml, p=0.3171). In conclusion AMH serum levels do not correlate with any of the observed parameters. AMH levels in seminal plasma positively correlate with the pathological SC and with SC pathology and IAE together. © 2016 Taylor & Francis. Source

Kucera R.,Laboratory of Immunoanalysis | Kucera R.,Charles University | Topolcan O.,Laboratory of Immunoanalysis | Topolcan O.,Charles University | And 10 more authors.
Clinica Chimica Acta

Background: IGF1 is responsible for regulation of growth, metabolism and differentiation of human cells. IGFBP3 is the most abundant of the carrier proteins for IGF1 in the blood. IGF1/IGFBP3 molar ratio is an indicator of IGF1 bioavailability. We decided to create a file of reference ranges of IGF1, IGFBP3 and IGF1/IGFBPP3 ratio for the adult Czech population across the age spectrum. Methods: We selected a group of 1022 subjects, 467 males and 555 females (ages 20-98. years), from several regions in the Czech Republic. The group consisted of blood donors and patients undergoing regular preventive examinations. Serum levels of IGF1 and IGFBP3 were measured using the following radioimmunoassay kits: IRMA IGF1 (Immunotech, Marseille, France) and IRMA IGFBP3 (Immunotech, Prague, Czech Republic). The IGF1/IGFBP3 ratio was also calculated. The following groups of patients were excluded: patients with diabetes, high blood glucose, high insulin levels, post-surgery patients, polymorbid patients, and subjects with oncological diseases. Subjects were divided into seven age-groups. Changes in the levels of observed analytes in each decade across the age spectrum were evaluated. All statistical analyses were performed by SAS 9.3 (Statistical Analysis Software release 9.3; SAS Institute Inc., Cary, NC, USA). Results: All three parameters IGF1, IGFBP3 and IGF1/IGFBP3 decreased in parallel with decrease in age: p<. 0.0001, r=. -. 0.64, -. 0.35 and -. 0.54, respectively. The dynamics of the decline was different between males and females.Linear regression models with age as independent variable fitted by gender are displayed in Fig. 1. Non-parametric reference interval curves (medians and 2.5th-97.5th percentiles) for IGF1, IGFBP3 and IGF1/IGFBP3 ratio as function of age by gender are displayed in Fig. 2(a,b,c). All medians and 2.5th-97.5th percentiles were plotted by cubic spline.For males, linear regression models were as follows: IGF1. =. 291.34619. -. 2.41211. ×. age, IGFBP3. =. 2931.62778. -. 6.11659. ×. age, IGF1/IGFBP3. =. 0.02897. -. 0.00021213. ×. age. For females, we plotted the following: IGF1. =. 241.67406. -. 1.98466. ×. age, IGFBP3. =. 3688.60561. -. 16.39560. ×. age, IGF1/IGFBP3. =. 0.02029. -. 0.00013233. ×. age.IGF1 was statistically significantly higher in males with p<. 0.0001 (Wilcoxon test) but decreased faster (. p=. 0.0121). IGFBP3 was statistically significantly higher in females with p=. 0.0004 (Wilcoxon test) but decreased faster (. p<. 0.0001). IGF1/IGFBP3 was statistically significantly higher in males with p<. 0.0001 (Wilcoxon test) but decreased faster (. p<. 0.0001). Conclusion: Authors recommend using of a linear regression model based reference ranges for IGF1, IGFBP3 and IGF1/IGFBP3 ratio and using different reference ranges for genders. © 2015 Elsevier B.V. Source

Discover hidden collaborations